The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The head office and logo of Valeant Pharmaceutical are pictured in Montreal on Monday May 27, 2013.
The head office and logo of Valeant Pharmaceutical are pictured in Montreal on Monday May 27, 2013.
(Ryan Remiorz/CP)

Signs point to health-care M&A revival

Valeant Pharmaceuticals International Inc.’s $8.7-billion (U.S.) bid for eye-care company Bausch & Lomb Inc. on Monday wasn’t just the largest purchase ever made by the deal-hungry company, it also made the list of top-ten mergers and acquisitions announced around the world this year.

And it’s not alone. Health-care targets now make up four of the top ten spots in the global ranking of M&A, according to Thomson Reuters numbers pulled on May 28 -- deals worth nearly $46-billion.